{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:38:59Z","timestamp":1793047139424,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste","award":["RC24\/17"],"award-info":[{"award-number":["RC24\/17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40272-019-00337-7","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T06:02:51Z","timestamp":1558591371000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-019X","authenticated-orcid":false,"given":"M.","family":"Bevacqua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-3154","authenticated-orcid":false,"given":"F.","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-0777","authenticated-orcid":false,"given":"S.","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-8014","authenticated-orcid":false,"given":"E.","family":"Valencic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-7927","authenticated-orcid":false,"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-8093","authenticated-orcid":false,"given":"A.","family":"Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-5538","authenticated-orcid":false,"given":"M.","family":"Rabusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-580X","authenticated-orcid":false,"given":"A.","family":"Arbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6343-846X","authenticated-orcid":false,"given":"E.","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"1\u20134","key":"337_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","volume":"1","author":"LM Ballou","year":"2008","unstructured":"Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1\u20134):27\u201336.","journal-title":"J Chem Biol."},{"issue":"1","key":"337_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/acel.12405","volume":"15","author":"SI Arriola Apelo","year":"2016","unstructured":"Arriola Apelo SI, Neuman JC, Baar EL, Syed FA, Cummings NE, Brar HK, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15(1):28\u201338.","journal-title":"Aging Cell."},{"issue":"7","key":"337_CR3","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/ASN.2007111202","volume":"19","author":"O Johnston","year":"2008","unstructured":"Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19(7):1411\u20138.","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"337_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1399-0012.2007.00686.x","volume":"21","author":"G Tenderich","year":"2007","unstructured":"Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant. 2007;21(4):536\u201343.","journal-title":"Clin Transplant."},{"issue":"450","key":"337_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cca.2015.07.022","volume":"23","author":"L Millner","year":"2015","unstructured":"Millner L, Rodriguez C, Jortani SA. A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: towards personalized medicine, immunosuppression and pharmacogenomics. Clin Chim Acta. 2015;23(450):15\u20138.","journal-title":"Clin Chim Acta."},{"issue":"8656","key":"337_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","volume":"2","author":"RY Calne","year":"1989","unstructured":"Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, et al. Rapamycin for immunosuppression in organ allografting. Lancet. 1989;2(8656):227.","journal-title":"Lancet."},{"issue":"2","key":"337_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jpeds.2005.04.017","volume":"147","author":"L Bindl","year":"2005","unstructured":"Bindl L, Torgerson T, Perroni L, Youssef N, Ochs HD, Goulet O, et al. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr. 2005;147(2):256\u20139.","journal-title":"J Pediatr."},{"issue":"4","key":"337_CR8","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/MPH.0000000000000785","volume":"39","author":"J Cayrol","year":"2017","unstructured":"Cayrol J, Garrido Colino C. Use of sirolimus (rapamycin) for treatment of cytopenias and lymphoproliferation linked to autoimmune lymphoproliferative syndrome (ALPS). Two case reports. J Pediatr Hematol Oncol. 2017;39(4):e187\u201390.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"337_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaoncol.2016.5299","volume":"3","author":"HJ West","year":"2017","unstructured":"West HJ. Novel precision medicine trial designs: umbrellas and baskets. JAMA Oncol. 2017;3(3):423.","journal-title":"JAMA Oncol."},{"issue":"12","key":"337_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646\u201357.","journal-title":"Blood."},{"issue":"2","key":"337_CR11","first-page":"97","volume":"34","author":"BB Lee","year":"2015","unstructured":"Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, et al. Diagnosis and treatment of venous malformations. Consensus document of the International Union of Phlebology (IUP): updated 2013. Int Angiol. 2015;34(2):97\u2013149.","journal-title":"Int Angiol."},{"issue":"3","key":"337_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/ped.13494","volume":"60","author":"A Nocerino","year":"2018","unstructured":"Nocerino A, Valencic E, Loganes C, Pelos G, Tommasini A. Low-dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome-associated infection. Pediatr Int. 2018;60(3):315\u20137.","journal-title":"Pediatr Int."},{"issue":"11","key":"337_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00431-006-0395-6","volume":"166","author":"A Taddio","year":"2007","unstructured":"Taddio A, Faleschini E, Valencic E, Granzotto M, Tommasini A, Lepore L, et al. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur J Pediatr. 2007;166(11):1195\u20137.","journal-title":"Eur J Pediatr."},{"issue":"12","key":"337_CR14","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","volume":"105","author":"M Battaglia","year":"2005","unstructured":"Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood. 2005;105(12):4743\u20138.","journal-title":"Blood."},{"issue":"5","key":"337_CR15","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.1542\/peds.2015-1132","volume":"136","author":"M Minute","year":"2015","unstructured":"Minute M, Patti G, Tornese G, Faleschini E, Zuiani C, Ventura A. Sirolimus therapy in congenital hyperinsulinism: a successful experience beyond infancy. Pediatrics. 2015;136(5):e1373\u20136.","journal-title":"Pediatrics."},{"issue":"1","key":"337_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","volume":"127","author":"KL Bride","year":"2016","unstructured":"Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17\u201328.","journal-title":"Blood."},{"issue":"1","key":"337_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101\u20136.","journal-title":"Br J Haematol."},{"issue":"1","key":"337_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.cdd.4401190","volume":"10","author":"F Rieux-Laucat","year":"2003","unstructured":"Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10(1):124\u201333.","journal-title":"Cell Death Differ."},{"issue":"5","key":"337_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10875-008-9196-1","volume":"28","author":"PL Yong","year":"2008","unstructured":"Yong PL, Russo P, Sullivan KE. Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol. 2008;28(5):581\u20137.","journal-title":"J Clin Immunol."},{"issue":"2","key":"337_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2350\/06-07-0130.1","volume":"10","author":"ML Heltzer","year":"2007","unstructured":"Heltzer ML, Choi JK, Ochs HD, Sullivan KE, Torgerson TR, Ernst LM. A potential screening tool for IPEX syndrome. Pediatr Dev Pathol. 2007;10(2):98\u2013105.","journal-title":"Pediatr Dev Pathol."},{"issue":"40","key":"337_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13052-014-0068-4","volume":"18","author":"D Zama","year":"2014","unstructured":"Zama D, Cocchi I, Masetti R, Specchia F, Alvisi P, Gambineri E, et al. Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) with intractable diarrhea. Ital J Pediatr. 2014;18(40):68.","journal-title":"Ital J Pediatr."},{"issue":"1","key":"337_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaci.2014.10.019","volume":"135","author":"LM Charbonnier","year":"2015","unstructured":"Charbonnier LM, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol. 2015;135(1):217\u201327.","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"337_CR23","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1111\/j.1399-3046.2011.01570.x","volume":"16","author":"HJ Bonatti","year":"2012","unstructured":"Bonatti HJ, Axt J, Hunter EB, Lott SL, Frangoul H, Gillis L, et al. Castleman disease in a pediatric liver transplant recipient: a case report and literature review. Pediatr Transplant. 2012;16(6):E229\u201334.","journal-title":"Pediatr Transplant."},{"key":"337_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clim.2016.07.017","volume":"171","author":"W Rae","year":"2016","unstructured":"Rae W, Ramakrishnan KA, Gao Y, Ashton-Key M, Pengelly RJ, Patel SV, et al. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase delta syndrome. Clin Immunol. 2016;171:38\u201340.","journal-title":"Clin Immunol."},{"issue":"6","key":"337_CR25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.jaip.2018.02.029","volume":"6","author":"E Valencic","year":"2018","unstructured":"Valencic E, Grasso AG, Conversano E, Lucafo M, Piscianz E, Gregori M, et al. Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. J Allergy Clin Immunol Pract. 2018;6(6):2165\u20137.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"12","key":"337_CR26","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1210\/jc.2016-2711","volume":"101","author":"M Szymanowski","year":"2016","unstructured":"Szymanowski M, Estebanez MS, Padidela R, Han B, Mosinska K, Stevens A, et al. mTOR inhibitors for the treatment of severe congenital hyperinsulinism: perspectives on limited therapeutic success. J Clin Endocrinol Metab. 2016;101(12):4719\u201329.","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"337_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1515\/jpem-2017-0148","volume":"30","author":"A Dastamani","year":"2017","unstructured":"Dastamani A, Guemes M, Walker J, Shah P, Hussain K. Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation. J Pediatr Endocrinol Metab. 2017;30(11):1219\u201322.","journal-title":"J Pediatr Endocrinol Metab."},{"issue":"4","key":"337_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/intimm\/dxm017","volume":"19","author":"C Xie","year":"2007","unstructured":"Xie C, Patel R, Wu T, Zhu J, Henry T, Bhaskarabhatla M, et al. PI3K\/AKT\/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int Immunol. 2007;19(4):509\u201322.","journal-title":"Int Immunol."},{"issue":"2","key":"337_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2015-11-685024","volume":"128","author":"S Volkl","year":"2016","unstructured":"Volkl S, Rensing-Ehl A, Allgauer A, Schreiner E, Lorenz MR, Rohr J, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128(2):227\u201338.","journal-title":"Blood."},{"issue":"6","key":"337_CR30","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","volume":"108","author":"DT Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108(6):1965\u201371.","journal-title":"Blood."},{"issue":"6","key":"337_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0031-3955(05)70272-8","volume":"47","author":"JJ Bleesing","year":"2000","unstructured":"Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin N Am. 2000;47(6):1291\u2013310.","journal-title":"Pediatr Clin N Am."},{"issue":"349","key":"337_CR32","doi-asserted-by":"publisher","first-page":"g6679","DOI":"10.1136\/bmj.g6679","volume":"24","author":"GA Knoll","year":"2014","unstructured":"Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;24(349):g6679.","journal-title":"BMJ."},{"issue":"5","key":"337_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00109-011-0834-3","volume":"90","author":"SB Yang","year":"2012","unstructured":"Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY, et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J Mol Med (Berl). 2012;90(5):575\u201385.","journal-title":"J Mol Med (Berl)."},{"issue":"Suppl 2","key":"337_CR34","first-page":"69","volume":"9","author":"H Demirbilek","year":"2017","unstructured":"Demirbilek H, Hussain K. Congenital hyperinsulinism: diagnosis and treatment update. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):69\u201387.","journal-title":"J Clin Res Pediatr Endocrinol."},{"issue":"7","key":"337_CR35","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, et al. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055\u201370.","journal-title":"Expert Opin Drug Saf."},{"issue":"8","key":"337_CR36","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","volume":"42","author":"AI Sanchez-Fructuoso","year":"2010","unstructured":"Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, Gomez Alamillo C, Calvo Romero N, Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc. 2010;42(8):3050\u20132.","journal-title":"Transplant Proc."},{"issue":"4","key":"337_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/TP.0b013e3182421604","volume":"93","author":"SG Piao","year":"2012","unstructured":"Piao SG, Bae SK, Lim SW, Song JH, Chung BH, Choi BS, et al. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation. 2012;93(4):383\u20139.","journal-title":"Transplantation."},{"issue":"69","key":"337_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-med-062016-050343","volume":"29","author":"JJ Tao","year":"2018","unstructured":"Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. 2018;29(69):319\u201331.","journal-title":"Annu Rev Med."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00337-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00337-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00337-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T23:31:53Z","timestamp":1590103913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00337-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00337-7","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"23 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr Bevacqua has nothing to disclose. Dr Baldo has nothing to disclose. Dr Pastore reports non-financial support from Abbvie, outside the submitted work. Dr Valencic has nothing to disclose. Dr Tommasini reports non-financial support from Novartis pharma, Kedrion, Shire, and CLS Behring, outside the submitted work. Dr Maestro has nothing to disclose. Dr Rabusin has nothing to disclose. Dr Arbo has nothing to disclose. Dr Barbi has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}